Pharmacokinetics of anthracyclines

Area of Science:

• Pharmacology
• Drug Metabolism and Pharmacokinetics
• Oncology

Background:

• Doxorubicin and 4'epi-doxorubicin are widely used anthracycline chemotherapeutics.
• Significant inter-individual variability exists in their plasma pharmacokinetics.
• Understanding these pharmacokinetic profiles is crucial for optimizing cancer treatment and minimizing toxicity.

Purpose of the Study:

• To investigate and compare the plasma pharmacokinetics of doxorubicin and 4'epi-doxorubicin.
• To evaluate the impact of different administration methods on drug exposure.
• To explore novel drug delivery systems for improved therapeutic outcomes.

Main Methods:

• Plasma samples analyzed using reversed-phase liquid chromatography with photometric detection.
• Simultaneous administration of both drugs for comparative pharmacokinetic analysis.
• Evaluation of intravenous bolus injection, 4-hour infusion, intrahepatic administration, and combination with biodegradable starch microspheres (Spherex).

Main Results:

• Both drugs follow a three-compartment open model with a terminal half-life of 20-30 hours.
• Doxorubicin exhibited higher average AUC (1.6x) and Cmax (1.2x) compared to 4'epi-doxorubicin.
• 4-hour infusion significantly decreased Cmax without affecting AUC; intrahepatic administration reduced both AUC and Cmax; Spherex decreased Cmax while maintaining AUC and increasing MRT.

Conclusions:

• Plasma pharmacokinetics of doxorubicin and 4'epi-doxorubicin show considerable inter-individual variation, necessitating personalized dosing.
• Administration route and formulation significantly influence drug exposure, with potential implications for efficacy and toxicity.
• Biodegradable starch microspheres show promise for enhancing tumor drug exposure by altering pharmacokinetic parameters.